MedTrace Logo

Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure

NCT07397650 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 550

Last updated 2026-02-11

No results posted yet for this study

Summary

FACILITATE-HF is a multicenter, randomized, double-blind, placebo-controlled trial designed to determine whether initiation of finerenone during the early phase of hospitalization has beneficial effects in patients with AHF who have left ventricular ejection fraction 40% or more.

Conditions

  • Acute Heart Failure

Interventions

DRUG

Finerenone Oral Tablet

For participants with an eGFR ≤60 mL/min/1.73 m\^2: Starting dose is 10 mg OD and maximum dose 20 mg OD. For participants with an eGFR \>60 mL/min/1.73 m\^2: Starting dose is 20 mg OD and maximum dose 40 mg OD.

DRUG

Finerenone Placebo

Placebo tablets matching finerenone are administered orally

Sponsors & Collaborators

  • Juntendo University

    lead OTHER

Principal Investigators

  • Yuya Matsue, MD · Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-28
Primary Completion
2027-12-31
Completion
2028-09-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07397650 on ClinicalTrials.gov